Lipopolysaccharide (LPS) protects from severe respiratory paramyxoviral viral infection through an innate immune response

Abstract

Respiratory diseases are among the leading causes of death and disability in the world. Understanding the anti-viral immune response is critical to relieve the morbidity and mortality burden of respiratory infections. Previous data using Sendai virus (SeV, murine parainfluenza virus type 1) suggested that pretreatment of C57BL6 wild-type (WT) mice with 0.1μg of lipopolysaccharide (LPS) prevented mortality from a normally lethal SeV infection. It is unknown if the protective effects of LPS are dependent on activation of innate immunity during the infection.